This novel, personalized hormone‑replacement therapy for anorexia nervosa (AN) simultaneously targets dysregulated ghrelin and leptin signaling using a transdermal skin‑patch delivery system. This represents a new device and treatment paradigm for AN, introducing both a previously undescribed hormone combination therapy and a precision‑medicine framework that tailors treatment based on epigenetic biomarkers, with strong translational potential supported by an existing, genomically characterized patient cohort.